Two products of Hansoh Pharmaceutical Group (HKG:3692) have received clinical trial approval from China's National Medical Products Administration, two filings with the Hong Kong bourse on Monday said.
Both drugs will be tested for the treatment of advanced solid tumors, according to the pharmaceutical company.
HS-20122 for injection will be investigated for tumors such as non-small cell lung cancer, head and neck squamous cell carcinoma, or colorectal cancer. HS-20108 for injection will be tested for the treatment of small cell lung cancer and neuroendocrine tumors.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。